Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 3Recurrence 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Immunoglobulin Light-chain Amyloidosis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Glioblastoma 1Fibrosis 1Fallopian Tube Neoplasms 1Dysplastic Nevus Syndrome 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Pharmaceutical Preparations × 1 year × Clear all
NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡